Nevertheless, the present study corroborates the idea that hydroxytyrosol could represent a promising compound to be tested in pre-clinical melanoma models, mainly in melanoma tumors with a predominant glycolytic metabolism and preference for JNK pathway activation. This evidence concerns the gene MAPK8 and melanoma.